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Objectives: An obesity paradox, a “paradoxical” decrease in morbidity and mortality
with increasing body mass index (BMI), has been shown in patients with cardio-
vascular diseases. However, whether this phenomenon exists in atrial ﬁbrillation (AF)
patients with concomitant heart failure (HF) is not known.
Methods: This study consecutively enrolled AF patients presenting to an emer-
gency department at 20 hospitals in China from Nov 2008 to Oct 2011. AF
concomitant HF patients were categorized as underweight (BMI<18.5), normal
(BMI 18.5 to <24), overweight (BMI 24 to <28), and obese (BMI 28 all
kg/m2). Multivariate Cox proportional hazards regression was used on all the
patients. End points of the analyses were all-cause mortality and cardiovascular
mortality.
Results: A total of 806 AF patients with concomitant HF were included in the
analysis, mean BMI was 23.34.1 kg/m2. A total of 153 deaths occurred over the
12-month follow-up, all-cause mortality was 19% in the whole patients, in under-
weight patients, normal weight, overweight, obese categories were 28.7%, 23.6%,
10.4%, and 11.8% respectively (P<0.001). The cardiovascular mortality in whole
patients was 14%, in underweight, normal weight, overweight, obese categories were
21.8%, 17.2%, 7.8% and 8.8% respectively (P¼0.001). On multivariate analysis, as a
continuous variable, BMI was not a risk factors for all-cause mortality (HR 0.91, 95%
CI 0.87-0.95; P<0.001), and for cardiovascular mortality (HR 0.91, 95% CI 0.86-
0.96; P<0.001); as a category variable, obesity (HR 0.50, 95% CI 0.26-0.94,
P¼0.032) and overweight (HR 0.40, 95% CI 0.25-0.63, P<0.001) were signiﬁcantly
associated with a lower risk of all-cause mortality, and overweight also with a lower
cardiovascular death (HR 0.45, 95% CI 0.26-0.76, P¼0.003) compared to normal
weight patients.
Conclusions: Our study showed an “obesity paradox” exists in AF patients with
concomitant HF. Obesity was not a risk factor for 12-month mortality in AF and HF
patients. Overweight AF patients have better survival and outcomes than normal
weight (BMI 18.5-24 kg/m2) patients.
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Objectives: Several clinical trials have evaluated the PDE5 inhibitors sildenaﬁl as a
potential adjunct in the treatment of heart failure (HF) with mixed results. Thus, we
conducted this meta-analysis to evaluate the clinical viability of sildenaﬁl in the
treatment of HF.
Methods: Relevant studies were searched and identiﬁed in the MEDLINE and
EMBASE databases. Randomized clinical trials (RCT) comparing sildenaﬁl to
placebo, in heart failure patients, reporting at least one outcome of interest
were included. Data were extracted regarding the characteristics and clinical
outcomes.
Results: We identiﬁed 9 RCTs enrolling 612 HF patients. There were no signiﬁcantly
difference in adverse events between sildenaﬁl group and placebo group (RR¼1.10,
95% CI 0.74-1.65, P¼0.41), whereas sildenaﬁl therapy was associated with a mark-
edly improvement in hemodynamics parameters peak VO2 (MD¼3.25, 95% CI 2.07-
4.42, P<0.00001) in HF with reduced ejection fraction (HFrEF) patients but not in HF
with preserved ejection fraction (HFpEF) patients. Also, sildenaﬁl therapy improved
VO2 at anaerobic threshold (AT) (MD¼3.47, 95% CI 1.68-5.27, P¼0.0002),
VE/VCO2 slope (MD¼-7.06, 95% CI -8.93- -5.19, P<0.00001) and LV ejection
fraction (MD¼5.43, 95% CI 3.66-7.20, P<0.00001) than placebo in HF patients,
which had no impact on blood pressure and heart rate. For quality of life (emotional
function, fatigue and breathlessness), there was no signiﬁcant difference between the
two groups.
Conclusions: Sildenaﬁl improved hemodynamic parameters particularly in HFrEF
patients comparing with placebo, yet with no increase in adverse events. Sildenaﬁl
treatment was well tolerated and had no impact on quality of life.
GW25-e3541
miR21* contributes to sepsis-induced cardiac dysfunction
Wang Hui, Xiangqing Kong
The First Afﬁliated Hospital of Nanjing Medical UniversityJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CObjectives: Sepsis-induced cardiac dysfunction is characterized by myocardial
inﬂammation and cardiac dysfunction. MicroRNAs (miRNAs, miRs), a class of non-
coding RNAs, has been reported to play important roles in a wide range of cell
functions including cell proliferation, differentiation, and apoptosis, making them
novel contributors for many human diseases. However, the role of miRNAs in sepsis-
induced cardiac dysfunction is unclear. This study aims at investigating the role of
miR21* in sepsis-induced cardiac dysfunction.
Methods: E.coli lipopolysaccharide (LPS) (5mg/kg) was administered to C57BL/6
mice to induce a sepsis-induced cardiac dysfunction model within 5-7 h. Cardiac
function was assessed by Echocardiography 5w6h post-LPS administration.
Myocardium were obtain within 7-9h after LPS treatment for gene expression and
protein analysis. A systematic analysis of cardiac miRNA proﬁles using an established
miRNAarray was performed to assess dys-regulated miRNAs in sepsis-induced car-
diac dysfunction. Transmission electron microscopy analysis was undertaken of
myocardium tissue. To forced expression of miR-21, miR-21 agomirs were injected in
the tail vein of C57B1/6J mice on 3 consecutive days with a total of 30nmol/kg agomir
followed by LPS administration.
Results: LPS induced a 15% reduction in factional shortening (%FS) and a 25%
decrease in ejection fraction (%EF). In addition, LPS leads to production of inﬂam-
matory cytokines such as TNF-a, IL-6 IL-1a and also reduces cardiac energy utili-
zation including FA oxidation and glucose metabolism. miRNA arrays indicated that
the expression level of miR21 was increased by 32 fold in sepsis-induced cardiac
dysfunction and the change of miR-21 was veriﬁcated by quantitative reverse tran-
scription polymerase chain reactions (RT-PCRs). Over-expression of miR-21 with
systemic delivery of agomir led to a 5% decrease in FS and a 9% decrease in EF as
compared to scramble control. Transmission electron microscopic micrographs of left-
ventricular tissues of miR21 agomir-LPS hearts presented signiﬁcantly myoﬁbril
disorientation and loss and lipid droplets. HE staining and PCR result of inﬂammatory
cytokines indicated that the aggravation of the LPS induced cardiac dysfunction by
miR21 agomir was not associated with alteration in inﬂammation. Interestingly,
elevation of miR-21 was also noted when NRCMs were exposed to LPS. Western
bloting indicated that the inhibition of miR21 in NRVM by 21 -antimiR, resulted in
the increase of PGC-1a. Conversely, over-expression of miR21 by 21 -mimic in
NRVM led to signiﬁcant inhibition of PGC-1a. These results indicate that PGC-1a is a
potential target gene for miR-21.
Conclusions: In conclusion, miR-21 contributes to sepsis-induced cardiac dysfunction
potentially via targeting PGC-1a. Targeting miR-21 might be a novel therapeutic
strategy for the treatment of sepsis-induced cardiac dysfunction and heart failure.
GW25-e2361
prevalence, predictors and prognostic signiﬁcance of early recovery of normal
left ventricular ejection fraction in patients with non-ischemic dilated
cardiomyopathy
Zou Changhong1, Wu Xuefei2, Huang Yan1, Zhou Qiong1, Wei Bingqi1, Zhang Yuhui1,
Lv Rong1, Zhang Jian1
1FuWai Hospital, National Center for Cardiovascular Diseases, 2Beijing Water
Conservancy Hospital
Objectives: The study was designed to determine the prevalence, predictors and
prognostic signiﬁcance of early recovery of normal left ventricular ejection fraction
(LVEF) in a cohort of Chinese patients with non-ischemic dilated cardiomyopathy
(NIDCM).
Methods: A total of 490 consecutive hospitalized patients with NIDCM and LVEF of
40% or less by echocardiography were evaluated by retrospectively reviewing the
electronic database of the institutional heart failure registry. Echocardiographic
and clinical data were available for 260 patients (53%) at the early follow-up
(94 months). Early recovery of normal LVEF was deﬁned as an increase in LVEF to
a level of 50% or greater within one year. An array of baseline variables regarded as
potentially relevant to recovery was evaluated to identify predictors of early recovery
using logistic regression analysis. The patients were followed thereafter for
2214 months to evaluate the long-term prognostic value of early recovery by means
of Cox hazard proportional model and receiver operating characteristic analysis.
Results: Early recovery of normal LVEF was found in 114 of 260 patients (44%) at a
mean follow-up period of 74 months, showing a signiﬁcant increase in LVEF from
30.45.8 % at baseline to 54.74.0 % at early follow-up (P<0.001), with a mean
increase of 24.26.7 %. This increase in LVEF was associated with a marked
decrease in left ventricular end-diastolic diameter (LVEDD) from 64.96.2 mm to
54.35.0 mm (P<0.001), with a mean decrease of 10.65.5 mm. Multivariate logistic
regression analysis showed that baseline independent predictors of early recovery
included a history of hypertension, shorter symptom duration, higher systolic blood
pressure at presentation and smaller LVEDD on echocardiogram. When added to a
prognostic baseline model including serum sodium on admission, right ventricular
diameter on echocardiogram and use of a beta-blocker on discharge, the presence of
early recovery of normal LVEF showed an additive prognostic value for long-term
combined clinical events of cardiovascular death or cardiac transplantation with
respect to baseline variables, as reﬂected by a signiﬁcant increase in the area under the
curve from 0.694 to 0.840 (P¼0.002).
Conclusions: Early recovery of normal LVEF, evident in up to 44% of our study
patients on contemporary medication, was associated with some baseline clinical and
echocardiographic parameters and signiﬁcantly improved the long-term prognostic
stratiﬁcation of NIDCM.ardiovascular Disease Clinical Research C181
